Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effect of Bimekizumab in Patients With Psoriasis Vulgaris and Active Psoriatic Arthritis Who Have an Inadequate Skin Response to Anti-IL23 Therapy

NCT05499416 is registered in ClinicalTrials.gov with Innovaderm Research Inc. as lead sponsor.

NCT NCT05499416
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05499416 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effect of Bimekizumab in Patients With Psoriasis Vulgaris and Active Psoriatic Arthritis Who Have an Inadequate Skin Response to Anti-IL23 Therapy
Lead sponsor
Innovaderm Research Inc.
Phase
Phase 4
Overall status
Withdrawn
Start date
January 31, 2023
Completion date
April 30, 2024
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

active psoriatic arthritis, psoriasis vulgaris